| Issue Date | Title | Author(s) |
| 2022-01 | GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol) | Conduit, C; Mak, B; Qu, W; Di Lulio, J; Burder, R; Bressel, M; Cusick, T; Dhillon, HM; De Abreu Lourenço, R; Underhill, C; Torres, J; Crumbaker, M; Honeyball, F; Linton, A; Allen, R; Davis, ID; Clark, SJ |
| 2022-05 | Supportive care of patients diagnosed with high grade glioma and their carers in Australia. | Halkett, GKB; Berg, MN; Daudu, D; Dhillon, HM; Koh, E-S; Ownsworth, T; Lobb, E; Phillips, J; Langbecker, D; Agar, M; Hovey, E; Moorin, R; Nowak, AK |
| 2023 | Bereavement outcomes of carers of patients with high grade glioma: Experiences of support before and after the death. | Lobb, EA; Halkett, GKB; McDougall, E; Campbell, R; Dhillon, HM; Phillips, JL; Nowak, AK |
| 2023-02 | Carer preparedness improved by providing a supportive educational intervention for carers of patients with high-grade glioma: RCT results. | Halkett, GKB; Lobb, EA; Phillips, JL; McDougall, E; Clarke, J; Campbell, R; Dhillon, HM; McGeechan, K; Hudson, P; King, A; Wheeler, H; Kastelan, M; Long, A; Nowak, AK; Care-IS Project Team, |
| 2023-08-21 | The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. | Roberts, MJ; Conduit, C; Davis, ID; Effeney, RM; Williams, S; Martin, JM; Hofman, MS; Hruby, G; Eapen, R; Gianacas, C; Papa, N; Lourenço, RDA; Dhillon, HM; Allen, R; Fontela, A; Kaur, B; Emmett, L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), |
| 2023-12-06 | Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. | Buteau, JP; Moon, D; Fahey, MT; Roberts, MJ; Thompson, J; Murphy, DG; Papa, N; Mitchell, C; De Abreu Lourenco, R; Dhillon, HM; Kasivisvanathan, V; Francis, RJ; Stricker, P; Agrawal, S; O'Brien, J; McVey, A; Sharma, G; Levy, S; Ayati, N; Nguyen, A; Lee, S-F; Pattison, DA; Sivaratnam, D; Frydenberg, M; Du, Y; Titus, J; Lee, S-T; Ischia, J; Jack, G; Hofman, MS; Emmett, L |
| 2023-02-20 | Trial in progress: PRESTIGE—Primary retroperitoneal lymph node dissection (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) and its impact on health-related quality of life (HRQoL) compared to chemotherapy or radiotherapy. | Conduit, C; Lewin, JH; Liow, ECH; Dhillon, HM; Hong, W; De Abreu Lourenço, R; Lawrentschuk, N; Thomas, B; Grimison, PS; Ahmadi, N; Sengupta, S; Tran, B |
